



INCIDENCE AND RISK FACTORS FOCUSING ON RADIOLOGY: REACTIONS AFTER EXPOSURE TO NON-IONIC CONTRAST MEDIA

Milena Theodoro¹, Daniele Cardoso dos Santos¹, Gabriel Teixeira Cagnin¹, Fabíola Garcia Praça² and Wanessa Silva Garcia Medina^{1*}

*¹Padre Albino University Center – UNIFIPA, Rua dos Estudantes, 255, 15809-144, Catanduva, SP, Brazil (wasigame@gmail.com).

²Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. do Café, s/n, 14040–903, Ribeirão Preto, SP, Brazil.

Article Received on
08 August 2018,

Revised on 28 August 2018,
Accepted on 18 Sept. 2018

DOI: 10.20959/wjpps201810-12498

*Corresponding Author

Wanessa Silva Garcia
Medina

Padre Albino University
Center – UNIFIPA, Rua dos
Estudantes, 255, 15809-144,
Catanduva, SP, Brazil
(wasigame@gmail.com).

ABSTRACT

Computed tomography (CT) imaging has rapidly become a commonplace diagnostic tool due to its utility in a wide range of diseases. To prospectively evaluate the incidence of reactions after exposure to Non-Ionic Contrast media (NICM), and to identify potential risk factors, with a focus on fasting duration for solid food and fluids, separately. **Methods:** From July to October 2017, 229 patients (117 men, 112 women; median age, 53.2 years; range, 04-90 years) undergoing ICM-enhanced CT were included in this study. Reactions after exposure to ICM exposure were assessed on a 3-point scale (mild, moderate, severe). Patients' characteristics and the fasting duration were evaluated to identify risk factors using logistic regression analysis. **Results:** Of the 229 patients, 8 experienced

hypersensitivity reaction, no patients experienced vomiting. Multi-variate regression analysis revealed that a history of drug hypersensitivity (3.49%) was independent risk factors for nausea. Of the patients who presented hypersensitivity reactions, 12.5% were diabetic, 12.5% had asthma, 50% had systemic arterial hypertension, 50% had dyslipidemia, 0% had renal disease, 25% had no associated alterations (asthma, hypertension, diabetes, dyslipidemia, renal diseases). **Conclusions:** The adverse reactions to ICM agents were consisting in predictors analyzers like an allergic history to contrast agents, diabetic, asthma, systemic arterial hypertension, dyslipidemia, renal disease and urticaria, history of the previous allergy

to drugs other than contrast agents. ICM Hypersensitive reactions occurred in 1.31% of patients. Our results showed that clinical decision based on patient clinical records resulted in a decrease of several immediate reactions incidence.

KEYWORDS: Hypersensitivity reaction, iodinated contrast media, non-ionic contrast media, case report, clinical history.

INTRODUCTION

Computed tomography (CT) imaging has rapidly become a commonplace diagnostic tool due to its utility in a wide range of diseases. Patients are frequently asked to fast prior to iodinated contrast media (ICM)- enhanced computed tomography (CT).^[1,2] A national survey in the United States estimates that approximately 70 million CT scan are performed per year.^[3] In Japan, the number of CT scans performed is not only substantially higher than in other countries but continues to increase.^[4,5] Previous study reported the number of CT scans performed was about 36,550,000 times a year.^[6] As the number of CT scanners increases, the number of diagnostic CT imaging studies increases as well as their side effects, including iatrogenic cancer^[7] and adverse events from iodine-containing contrast agents.^[8,9]

With the introduction of nonionic low-osmolality ICM, the reported frequency of immediate reactions (Like vomiting) has declined with varying range, from 1% or less to 11.7%, lessening the rationale of the fasting.^[1,10,14]

Symptoms of an adverse reaction to contrast agents are diverse ranging from flushing, pruritus, urticaria, and angioedema^[15], with more severe side effects including hypotension, loss of consciousness, to potentially life-threatening bronchospasm and airway obstruction.^[16] These adverse events are hypersensitivity reaction, and classified into allergic reactions and non-allergic reactions author reply^[17], the former, dependent on^[18], and the latter, independent on dose and infusion rate.^[19] Juchen and Dall'Agnol 2007 study about immediate adverse reactions to intravenous iodinated contrast media in hospitalized patients submitted to computed tomography at a teaching hospital in the South of Brazil. During the study period, all adverse reactions showed mild intensity, at a frequency of 12.5% with ionic iodinated contrast media, and 1% with non-ionic contrast agent. The extravasation of contrast occurred in 2.2% of the injections in a peripheral vein without complications in any of the cases.^[20] In this study, we focused on all kinds of adverse events for contrast agent for CT scans. Risk factors for these adverse effects have been reported in previous literature, with a

history of immediate adverse reaction to contrast agents being the most significant. A history of allergy-mediated disease, including asthma, atopic dermatitis, and urticaria, is also considered a significant risk factor.

METHODS

A retrospective cohort study of all patients who underwent contrast-enhanced CT imaging with contrast agents from July through October 2017 was conducted at patients undergoing clinical therapy in Department of Radiology at, in Catanduva-SP, Brazil. All potential prognostic prediction parameters were collected prior to imaging and were based on previous studies, as well as physician-driven clinical relevance. Parameters were composed of patients' 1) demographic data, 2) administered contrast agents, 3) allergic history, 4) medical history, and 5) immediate hypersensitive reactions. If patients underwent more than one CT scan during the study period, only the most recent data were included. Demographic data included gender and age. Data on contrast agents included a type of the agent, contrast agent concentration, and total contrast agent dose.^[21] Allergic history included any history of antibiotics or any other drug.^[15,22] Medical history included atopic dermatitis, renal disease, urticaria, asthma, hypertension, diabetes, and dyslipidemia.^[15,23] Adverse reactions to contrast agents are defined based on the previous study.^[24] Acute reactions which occur immediately during the injection of the contrast agents up to one hour afterwards were observed and documented by a trained radiologist or nurse in charge of the examination for several hours after imaging. Non-acute (delayed) reactions occur more than one hour after the injection of the contrast agent. After discharge, patients were followed up at home for any reactions occurring within 24 hours of contrast administration by self-reporting. Albeit infrequent, severe adverse reactions involving prolonged hypertension, angina, ventricular fibrillation, based on the previous study.^[25] We analyzed all kinds of these adverse reactions.

Statistical Analysis

Descriptive statistics were employed to characterize subjects' baseline data. In order to facilitate the use of the prediction rule in the clinical setting, continuous values were categorized into groups. Following the methodology of previous studies, laboratory test results and continuous values were dichotomized based on average values.^[26] Continuous variables were expressed as mean \pm standard deviation (SD). Categorical variables were expressed by percentages. The Student's t-test was used to compare quantitative variables. The values of $p < 0.05$ were considered statistically significant. Statistical analysis was

performed using the GraphPad Prism 5 Software for Windows. Ethical approval was obtained from the Research Ethics Committee of Faculdades Integradas Padre Albino, Catanduva-SP, Brazil (n^o: 1.219.448).

RESULTS AND DISCUSSION

Patient profiles

Two hundred and twenty-nine patients were studied in this work and separated into two distinct groups. The group 1 consisted of 204 with NICM, while the group 2 consisted of 25 patients that received ICM and 24% from these patients were re-exposed to ICM. The proportion of men in the studied population was 48.52 and 72% for group 1 and 2 (Figure 1) and the mean age of the studied population was also similar for the two groups which were in the range of 53.2 years old (Figure 2).




Figure 1: Proportion of men in the study.




Figure 2: Range age groups.

Immediate hypersensitivity reaction

Most importantly to prevent immediate hypersensitivity to ICM include the clinical history of previous immediate reaction to ICM.^[27] According to the literature, the term "iodine allergy" describes four different conditions such as allergy to ICM, allergy to disinfection, allergy to amiodarone and/or seafood (crustaceans or fish).^[28,31] Herein, the first question to be addressed was the analysis of the term and diagnosis of "iodine allergy" and it was evidenced an inexact, insufficient and imprecise documentation for diagnosis of iodine allergy. Only 1,31% of the patients (considering all studied groups) were documented to ICM allergy. Hypersensitivity reactions after application of both ICM and NICM contrast were evaluated considering all patients studied and 5 patients from Group 1 (0,98%) experienced hypersensitivity reaction while only 3 patient from Group 2 (12%) experienced a grade I reaction to ICM. Furthermore, medical history included atopic dermatitis, renal disease, urticaria, asthma, hypertension, diabetes, and dyslipidemia were demonstrated at Table 1. Acute reactions and Non-acute (delayed). Albeit infrequent, were analyzed all kinds of these adverse reactions.

Table 1: Checklist of baseline parameters.

	Yes (%)	No (%)
Hypersensitivity Reaction	3.49	96.5
Already used ICM before	42.79	57.2
Asthma / Bronchite	3.93	96.06
Cardiac	6.98	93.01
Systemic Arterial Hypertension (SAH)	40.61	59.38
Renal Disease	3.05	96.94
Diabetic	14.84	85.15
Dyslipidemia	8.29	91.7
Gender	Male(%)	Female (%)
	51.09	48.9
Type of contrast	ICM (%)	NICM (%)
	10.91	89.08

Our group studied in recent about the immediate hypersensitivity to iodinated contrast media or non-ionic contrast reduced by clinical history, and they observed that the prediction rule may facilitate the pre- and post-imaging management of patients requiring contrast-enhanced CT imaging. For instance, physicians can consider whether they prescribe pre-medications for high-risk patients based on the rule. In other examples, physicians may choose the perform CT scans without contrast agent. Finally, physicians can evaluate which patients they should observe carefully and for a long time after CT scans.^[32]

CONCLUSION

The adverse reactions to ICM agents were consisting in predictors analyzers like an allergic history to contrast agents, diabetic, asthma, systemic arterial hypertension, dyslipidemia, renal disease and urticaria, history of previous allergy to drugs other than contrast agents. ICM Hypersensitive reactions occurred in 1.31% of patients and none vomited in our study population. The results are within the limits cited in the international literature and suggest that tomography service professionals should know their own rates of adverse reactions to iodinated contrast agent, as well as the conditions in which they occur, in order to obtain evidence to evaluate the respective care delivery processes. However, in our study, few patients had documented clinical history of immediate response to ICM and they received a premedication before re-exposure to ICM or even received ICM replacement by NICM. In conclusion, our results showed that clinical decision based on patient clinical records resulted in a decrease of several immediate reactions incidence.

REFERENCES

1. Lee B-Y, Ok J-J, Abdelaziz Elsayed AA, et al. Preparative fasting for contrast-enhanced CT: reconsideration. *Radiology*, 2012; 263(2): 444-50.
2. Wagner H, Evers J, Hoppe M, et al. Must the patient fast before intravascular injection of a non-ionic contrast medium? Results of a controlled study. *RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin*, 1997; 166(5): 370-75.
3. Berrington de González A1, Mahesh M, Kim KP, Bhargavan M, Lewis R, Mettler F, Land C. Projected cancer risks from computed tomographic scans performed in the United States in 2007. *Arch Intern Med.*, 2009 Dec. 14; 169(22): 2071-7.
4. Berrington De Gonzalez A, Darby S: Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. *Lancet*, 2004; 363: 345–351.
5. Ono K, Yoshitake T, Hasegawa T, Ban N, Kai M: Estimation of the number of CT procedures based on a nationwide survey in Japan. *Health Phys.*, 2011; 100: 491–496.
6. Nishizawa KMM, Maruyama T, et al: Survey of CT Practice in Japan and Collective Effective Dose Estimation. *Jpn J Radiol*, 2004; 64: 151–158.
7. Brenner D, Elliston C, Hall E, Berdon W: Estimated risks of radiation-induced fatal cancer from pediatric CT. *AJR Am J Roentgenol*, 2001; 176: 289–296.
8. Barrett BJ: Contrast nephrotoxicity. *J Am Soc Nephrol*, 1994; 5: 125–137.
9. Cochran ST: Anaphylactoid reactions to radiocontrast media. *Curr Allergy Asthma Rep.*, 2005; 5: 28–31.

10. Hitoshi Katayama M. Adverse reactions to ionic and non-ionic contrast media—a report from the Japanese committee on safety of contrast media. *Radiology*, 1990; 175: 621-28.
11. Maurer M, Heine O, Wolf M, et al. Safety and tolerability of iobitridol in general and in patients with risk factors: Results in more than 160000 patients. *European journal of radiology*, 2011; 80(2): 357-62.
12. Palkowitsch PK, Bostelmann S, Lengsfeld P. Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients. *Acta Radiologica*, 2014; 55(6): 707-14.
13. de Geeter P, Melchior H. Iomeprol versus iopromide for intravenous urography. *Br J Radiol*, 1994; 67(802): 958-63. doi: <https://doi.org/10.1259/0007-1285-67-802-958> [published Online First: 1994/10/01]
14. Garcia M, Aguirre U, Martinez A, et al. Acute adverse reactions to iopromide vs iomeprol: a retrospective analysis of spontaneous reporting from a radiology department. *Br J Radiol*, 2014; 87(1033): 20130511.
15. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K: Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. *Radiology*, 1990; 175: 621–628.
16. Hagan JB: Anaphylactoid and adverse reactions to radiocontrast agents. *Immunol Allergy Clin North Am*, 2004; 24: 507–519. vii-viii.
17. Bohm I, Schild H: ontrast-media-induced hypersensitivity or allergic/ allergic-like reactions? Suggestion for a more appropriate use of the nomenclature. *Eur J Clin Pharmacol*, 2008; 64: 931–932.
18. Sandow BA, Donnal JF: Myelography complications and current practice patterns. *AJR Am J Roentgenol*, 2005; 185: 768–771.
19. Federle MP, Willis LL, Swanson DP: Ionic versus nonionic contrast media: a prospective study of the effect of rapid bolus injection on nausea and anaphylactoid reactions. *J Comput Assist Tomogr*, 1998; 22: 341–345.
20. Juchem BC, Dall’Agnol CM. Immediate adverse reactions to intravenous iodinated contrast media in computed tomography. *Rev Latino-am Enfermagem 2007 janeiro-fevereiro*, 15(1): 78-83.
21. Cohan RH, Leder RA, Ellis JH: Treatment of adverse reactions to radiographic contrast media in adults. *Radiol Clin North Am*, 1996; 34: 1055–1076.

22. Witten DM, Hirsch FD, Hartman GW: Acute reactions to urographic contrast medium: incidence, clinical characteristics and relationship to history of hypersensitivity states. *Am J Roentgenol Radium Ther Nucl Med*, 1973; 119: 832–840.
23. Bettmann MA, Heeren T, Greenfield A, Goudey C: Adverse events with radiographic contrast agents: results of the SCVIR Contrast Agent Registry. *Radiology*, 1997; 203: 611–620.
24. Schild HH, Kuhl CK, Hubner-Steiner U, Bohm I, Speck U: Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial. *Radiology*, 2006; 240: 56–64.
25. Bohm I, Alfke H, Klose KJ: Hypersensitivity reactions and contrast medium injection: are they always related? *Eur J Radiol*, 2011; 80: 368–372.
26. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD: Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. *J Clin Epidemiol*, 2001; 54: 774–781.
27. Yasuda R, Munechika H. Delayed Adverse Reactions To Nonionic Monomeric Contrast-Enhanced Media. *Invest Radiol*, 1998; 33: 1–5.
28. Beaty AD, Lieberman PL, Slavin RG. Seafood Allergy And Radiocontrast Media: Are Physicians Propagating A Myth *Am J Med*, 2008; 121: 158 E151–158.
29. Baig M, Farag A, Sajid J et al. Shellfish allergy and relation to iodinated contrast media: united kingdom survey. *World J Cardiol.*, 2014; 6: 107–111.
30. Brouse SD, Phillips SM. Amiodarone use in patients with documented allergy to iodine-containing compounds. *Pharmacotherapy*, 2005; 25: 429–434.
31. Lakshmanadoss U, lindsley J, glick D et al. Incidence of amiodarone hypersensitivity in patients with previous allergy to iodine or iodinated contrast agents. *Pharmacotherapy*, 2012; 32: 618–622.
32. Ana Paula Melo de Assis, Mariana Rosa Canozzo, Marcos Vinicius Melo de Assis, Fabíola Garcia Praça Wanessa Silva Garcia Medina. Immediate Hypersensitivity To Iodinated Contrast Media Or Non Ionic Contrast Reduced By Clinical History. *Indian Journal of Medical Research and Pharmaceutical Sciences*, 2017; 4(11): 1–7.